Share price · XNCR
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when XNCR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 4 Nov 2026+14.3%
- 26 Oct 2026+15.9%
- 18 Aug 2026+9.9%
Nothing announced by XNCR that day or the session before.
- 30 Jul 2026+10.0%
- 20 Jul 2026+7.7%
- 17 Jul 2026+16.9%
- 8 Jul 2026+5.0%
Nothing announced by XNCR that day or the session before.
- 22 Jun 2026+10.8%
- 1 May 2026+6.4%
Nothing announced by XNCR that day or the session before.
- 5 Mar 2026-12.4%
Share of unusual movement by asset
For each asset, the share of XNCR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(6 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | CD19Monoclonal antibody | Diffuse Large B-Cell LymphomaFollicular LymphomaNon-Hodgkin Lymphoma Large B-Cell Lymphoma | |
| Phase 1/2 | TL1AMonoclonal antibody | Inflammatory Bowel Disease Ulcerative Colitis | |
| Phase 1 | CD20 x CD3Multispecific antibody | Rheumatoid Arthritis | |
| Phase 1 | Claudin 6 (CLDN6) x CD3Multispecific antibody | Ovarian Cancer | |
| Phase 1 | CD19 x CD3Multispecific antibody | Idiopathic Inflammatory Myopathies | |
| Phase 1 | ENPP3 x CD3Multispecific antibody | Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $117M | $84M | $65M+ $318M short-term inv. | —$2.6M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $51M | $72M | $45M+ $333M short-term inv. | $22M-$56M operating cash flow | report ↗ |
| 2026-Q1 | $4.5M | $65M | $542M+ $370M short-term inv. | $129M-$68M operating cash flow | report ↗ |
| 2025-Q3 | $21M | $54M | $29M+ $358M short-term inv. | $6.0M-$31M operating cash flow | report ↗ |
| 2025-Q2 | $44M | $62M | $45M+ $359M short-term inv. | $31M-$36M operating cash flow | report ↗ |
| 2025-Q1 | $33M | $59M | $40M+ $381M short-term inv. | $48M-$16M operating cash flow | report ↗ |
| 2024-Q3 | $11M | $58M | $29M+ $435M short-term inv. | $45M-$26M operating cash flow | report ↗ |
| 2024-Q2 | $17M | $62M | $31M+ $449M short-term inv. | $66M-$65M operating cash flow | report ↗ |
| 2024-Q1 | $13M | $57M | $31M+ $460M short-term inv. | $68M-$55M operating cash flow | report ↗ |
| 2023-Q3 | $59M | $65M | $53M+ $413M short-term inv. | $24M-$27M operating cash flow | report ↗ |
| 2023-Q2 | $46M | $60M | $35M+ $477M short-term inv. | $22M-$38M operating cash flow | report ↗ |
| 2023-Q1 | $19M | $64M | $72M+ $476M short-term inv. | $61M-$31M operating cash flow | report ↗ |
| 2022-Q3 | $27M | $53M | $53M+ $515M short-term inv. | $33M-$1.2M operating cash flow | report ↗ |
| 2022-Q2 | $30M | $47M | $49M+ $436M short-term inv. | $34M$44M operating cash flow | report ↗ |
| 2022-Q1 | $86M | $48M | $78M+ $278M short-term inv. | —$5.8M operating cash flow | report ↗ |
| 2021-Q3 | $20M | $51M | $41M | $40M-$39M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $126M | $239M | $54M+ $381M short-term inv. | $23M-$135M operating cash flow | report ↗ |
For FY2025, Xencor reported revenue of $125.58M, up 13.7% YoY from $110.49M. R&D spend was $239.43M, up 5.2% YoY from $227.69M. Cash and equivalents totaled $54.36M, with a net loss of $91.92M and quarterly net burn of $91.92M.
During the year, Xencor presented initial Phase 1 data for XmAb819 in clear cell renal cell carcinoma and early efficacy data for XmAb541 in gynecologic and germ cell tumors, initiated a global Phase 2b study (XENITH-UC) of XmAb942 in ulcerative colitis after reporting healthy-volunteer data, started a Phase 1b proof-of-concept study of plamotamab in rheumatoid arthritis, and initiated a Phase 1 study of XmAb657 in idiopathic inflammatory myopathies. The company selected XmAb412 as its lead TL1A x IL23p19 bispecific candidate, paused further development of vudalimab, and decided not to initiate expansion cohorts of XmAb808 in combination with pembrolizumab. Partner updates included FDA approval of Monjuvi in relapsed/refractory follicular lymphoma, positive pivotal results for obexelimab in IgG4-RD and relapsing multiple sclerosis, and Incyte’s expected sBLA filing for first-line DLBCL in the first half of 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $110M | $228M | $41M+ $409M short-term inv. | $58M-$202M operating cash flow | report ↗ |
| 2023-FY | $168M | $254M | $54M+ $498M short-term inv. | $32M$85M operating cash flow | report ↗ |
| 2022-FY | $165M | $200M | $54M+ $527M short-term inv. | $14M$24M operating cash flow | report ↗ |
| 2021-FY | $275M | $193M | $143M+ $154M short-term inv. | —-$17M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 21 sales ($7.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-11 | Cornelissen Bart Jan · SR. VICE PRESIDENT & CFO | Open-market sale | 10,100 | $39.82 | $402K | Form 4 |
| 2026-11-10 | RANIERI RICHARD J · director | Option exercise | 15,000 | $23.04 | $346K | Form 4 |
| 2026-11-10 | RANIERI RICHARD J · director | Option exercise | 21,412 | $26.58 | $569K | Form 4 |
| 2026-11-10 | RANIERI RICHARD J · director | Option exercise | 11,971 | $21.31 | $255K | Form 4 |
| 2026-11-10 | RANIERI RICHARD J · director | Option exercise | 27,372 | $9.43 | $258K | Form 4 |
| 2026-11-10 | RANIERI RICHARD J · director | Open-market sale | 70,080 | $39.20 | $2.7M | Form 4 |
| 2026-11-10 | RANIERI RICHARD J · director | Open-market sale | 11,172 | $39.59 | $442K | Form 4 |
| 2026-11-10 | RANIERI RICHARD J · director | Option exercise (derivative) | 15,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 203 reporting institutions held 84.5M shares ($988.9M, 112.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 13,035,918 | $157.2M |
| 2 | PRIMECAP MANAGEMENT CO/CA/ | 10,338,022 | $124.7M |
| 3 | BVF INC/IL | 7,133,720 | $86.0M |
| 4 | RTW INVESTMENTS, LP | 6,777,461 | $81.7M |
| 5 | RA CAPITAL MANAGEMENT, L.P. | 4,897,237 | $59.1M |
| 6 | STATE STREET CORP | 4,352,036 | $52.5M |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3,500,342 | $42.2M |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 3,101,647 | $37.4M |
| 9 | TCG Crossover Management, LLC | 2,452,138 | $29.6M |
| 10 | EcoR1 Capital, LLC | 2,183,000 | $26.3M |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 1,815,577 | $21.9M |
| 12 | MORGAN STANLEY | 1,558,290 | $18.8M |
| 13 | DIMENSIONAL FUND ADVISORS LP | 1,294,887 | $15.6M |
| 14 | BAKER BROS. ADVISORS LP | 1,102,106 | $13.3M |
| 15 | UBS Group AG | 1,082,419 | $13.1M |